Literature DB >> 21704130

Neuroactive steroids: focus on human brain.

R C Melcangi1, G Panzica, L M Garcia-Segura.   

Abstract

Studies in experimental animals have revealed important roles of neuroactive steroids in the control of central nervous system functions during physiological and pathological conditions, suggesting that they may represent good candidates for the development of neuroprotective strategies for neurodegenerative and psychiatric disorders. Even if the characterization of the roles played by neuroactive steroids in humans is still at the beginning, several data are already available showing that they may be synthesized within the human CNS. Among the different enzymes, a prominent role is dedicated to aromatase that synthesizes estradiol whose neuroprotective effects have been described in experimental animals. Neuroactive steroid levels are modified by neurodegenerative conditions (i.e. Alzheimer's and Parkinson's diseases, multiple sclerosis) or in other mental diseases (i.e. schizophrenia), and may have an important role in physiological conditions, as the reorganization of grey and white matter during human puberty and adolescence or as a consequence of emotional responses. The interaction of some neuroactive steroids (i.e., allopregnanolone and isopregnanolone) with GABA-A receptor is particularly important in mood disorders. The presumptive role of estradiol and progesterone in neuroprotection is here discussed by comparing contradictory data that have been collected in humans. In conclusion, the state of the art of our knowledge of the role of neuroactive steroids in the normal and pathological human brain suggests several lines of future therapeutic developments in the treatments of neurological, neurodegenerative and affective disorders. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704130     DOI: 10.1016/j.neuroscience.2011.06.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.

Authors:  Richard S Legro; Allen R Kunselman; Robert G Brzyski; Peter R Casson; Michael P Diamond; William D Schlaff; Gregory M Christman; Christos Coutifaris; Hugh S Taylor; Esther Eisenberg; Nanette Santoro; Heping Zhang
Journal:  Contemp Clin Trials       Date:  2012-01-13       Impact factor: 2.226

Review 2.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 3.  The development of psychotic disorders in adolescence: a potential role for hormones.

Authors:  Hanan D Trotman; Carrie W Holtzman; Arthur T Ryan; Daniel I Shapiro; Allison N MacDonald; Sandra M Goulding; Joy L Brasfield; Elaine F Walker
Journal:  Horm Behav       Date:  2013-07       Impact factor: 3.587

Review 4.  Insights into rapid modulation of neuroplasticity by brain estrogens.

Authors:  Deepak P Srivastava; Kevin M Woolfrey; Peter Penzes
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

5.  Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins.

Authors:  Richard S Legro; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; R Mitchell Rosen; Marcelle I Cedars; Karl R Hansen; Randal Robinson; Valerie Baker; Rebecca Usadi; William C Dodson; Stephanie J Estes; Allen Kunselman; Christina Stetter; Kurt T Barnhart; R Matthew Coward; J C Trussell; Stephen A Krawetz; Nanette Santoro; Hao Huang; Heping Zhang; Esther Eisenberg
Journal:  Fertil Steril       Date:  2020-05       Impact factor: 7.329

Review 6.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

Review 7.  Sex differences in anxiety and emotional behavior.

Authors:  Nina C Donner; Christopher A Lowry
Journal:  Pflugers Arch       Date:  2013-04-16       Impact factor: 3.657

8.  Hippocampal atrophy and subsequent depressive symptoms in older men and women: results from a 10-year prospective cohort.

Authors:  Martine Elbejjani; Rebecca Fuhrer; Michal Abrahamowicz; Bernard Mazoyer; Fabrice Crivello; Christophe Tzourio; Carole Dufouil
Journal:  Am J Epidemiol       Date:  2014-08-01       Impact factor: 4.897

Review 9.  Liver X receptors, nervous system, and lipid metabolism.

Authors:  G Cermenati; E Brioschi; F Abbiati; R C Melcangi; D Caruso; N Mitro
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

10.  Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study.

Authors:  Elaine F Walker; Hanan D Trotman; Brad D Pearce; Jean Addington; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Daniel H Mathalon; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Tyrone D Cannon; Thomas H McGlashan; Scott W Woods
Journal:  Biol Psychiatry       Date:  2013-04-03       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.